Pancreatic Cancer Research

ResearcherChiba UniversityActive in the last 2 years

Masayuki Ohtsuka

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5091-1078; OpenAlex author ID A5051169610. Sources: OpenAlex.

Their work

Papers
57 (first author 0, last author 28)
Trials
0
Grants
0
Labs led
1
Collaborators
169
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 1 paper · 2015: 3 papers · 2016: 4 papers · 2017: 5 papers · 2018: 3 papers · 2019: 3 papers · 2020: 4 papers · 2021: 7 papers · 2022: 3 papers · 2023: 5 papers · 2024: 5 papers · 2025: 8 papers · 2026: 5 papers

Papers 50 of 57

  1. Complement Factor B Blockade by Iptacopan Drives Antitumor Complement-Based Immunomodulation in Pancreatic Cancer Microenvironment. Last author DOI 10.1016/j.ajpath.2026.08.005↗
  2. International multicenter validation of an 18F-fluorodeoxyglucose positron emission tomography/computed tomography maximum standardized uptake value 4.0 thresh… Last author DOI 10.1016/j.surg.2026.110503↗
  3. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  4. Prognostic Impact of Unplanned Hospitalization During First-Line Gemcitabine Plus Nab-Paclitaxel Therapy for Unresectable Pancreatic Cancer: A Single-Center Re… Co-author DOI 10.3390/cancers18020194↗
  5. Tumor-associated tissue-resident macrophages drive pancreatic cancer progression through IGF1-IGF1R signaling Co-author DOI 10.64898/2026.05.08.723679↗
  6. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  7. A pancreatic cancer organoid incorporating macrophages reveals the correlation between the diversity of tumor-associated macrophages and cancer cell survival. Co-author DOI 10.1016/j.biomaterials.2024.122838↗
  8. Protocol for generating a pancreatic cancer organoid associated with heterogeneous tumor microenvironment. Co-author DOI 10.1016/j.xpro.2024.103539↗
  9. Inhibition of C5a-C5aR1 axis suppresses tumour progression by enhancing antitumour immunity and chemotherapeutic effect in pancreatic ductal adenocarcinoma. Last author DOI 10.1038/s41416-025-03185-0↗
  10. Three Molecular Developmental Pathways of Remnant Pancreatic Cancer After Resection: A Nationwide Project Study of Japan Pancreas Society. Co-author DOI 10.1097/sla.0000000000006444↗
  11. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  12. Serum fucosylated receptor expression-enhancing protein 5 as a biomarker for early stage pancreatic cancer. Co-author DOI 10.3892/ol.2025.15302↗
  13. Long-Term Survival after Curative Resection for Postoperative Dissemination of Pancreatic Ductal Adenocarcinoma: A Case Report. Last author DOI 10.70352/scrj.cr.24-0022↗
  14. Outcomes of patients with initially unresectable pancreatic cancer who underwent conversion surgery after FOLFIRINOX or gemcitabine plus nab-paclitaxel chemoth… Co-author DOI 10.1002/jhbp.12066↗
  15. ECM1 and KRT6A are involved in tumor progression and chemoresistance in the effect of dexamethasone on pancreatic cancer. Co-author DOI 10.1111/cas.16175↗
  16. Preoperative Prediction of Long-Term Survival After Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-024-15648-4↗
  17. ASO Author Reflections: Importance of Preoperative Prediction of Survival in Resectable Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1245/s10434-024-15853-1↗
  18. [Ⅳ. Recent Topics of Precision Medicine for Patients with Pancreatic Cancer]. Last author PMID 39571982↗
  19. Features of T1 pancreatic cancer and validation of the eighth edition AJCC staging system definition using a Korean-Japanese joint cohort and the SEER database. Co-author DOI 10.1002/jhbp.1316↗
  20. Clinical benefits of pulmonary resection for lung metastases from pancreatic cancer. Last author DOI 10.1007/s00423-023-03198-4↗
  21. Complex glandular pattern is an aggressive morphology that predicts poor prognosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.anndiagpath.2023.152110↗
  22. Incorporation of human iPSC-derived stromal cells creates a pancreatic cancer organoid with heterogeneous cancer-associated fibroblasts. Co-author DOI 10.1016/j.celrep.2023.113420↗
  23. Semaphorin 3 C enhances putative cancer stemness and accelerates peritoneal dissemination in pancreatic cancer. Last author DOI 10.1186/s12935-023-03008-3↗
  24. The effect of the low stromal ratio induced by neoadjuvant chemotherapy on recurrence patterns in borderline resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s10585-021-10142-7↗
  25. Prosaposin, tumor-secreted protein, promotes pancreatic cancer progression by decreasing tumor-infiltrating lymphocytes. Last author DOI 10.1111/cas.15444↗
  26. [Ⅰ. Recent Trends in Chemotherapy followed by Surgery for Patients with Locally Advanced Biliary-Pancreatic Cancer]. Last author PMID 36281595↗
  27. Complement factor B regulates cellular senescence and is associated with poor prognosis in pancreatic cancer. Last author DOI 10.1007/s13402-021-00614-z↗
  28. Analysis of circulating cell-free DNA after endoscopic ultrasound-guided fine needle aspiration in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2021.04.001↗
  29. PTHrP Drives Pancreatic Cancer Growth and Metastasis and Reveals a New Therapeutic Vulnerability. Co-author DOI 10.1158/2159-8290.cd-20-1098↗
  30. Simultaneous brain and lung metastases of pancreatic ductal adenocarcinoma after curative pancreatectomy: a case report and literature review. Last author DOI 10.1186/s12876-020-01587-3↗
  31. C4b-binding protein α-chain enhances antitumor immunity by facilitating the accumulation of tumor-infiltrating lymphocytes in the tumor microenvironment in pan… Last author DOI 10.1186/s13046-021-02019-0↗
  32. Fucosylated C4b-binding protein α-chain, a novel serum biomarker that predicts lymph node metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.3892/ol.2020.12388↗
  33. [Ⅲ.Surgical Treatment for Recurrence of Pancreatic Cancer]. Last author PMID 34657053↗
  34. Comparing prognostic factors of Glut-1 expression and maximum standardized uptake value by FDG-PET in patients with resectable pancreatic cancer. Last author DOI 10.1016/j.pan.2020.07.407↗
  35. Diverse transitions in diabetes status during the clinical course of patients with resectable pancreatic cancer. Co-author DOI 10.1093/jjco/hyaa136↗
  36. Endoscopic Ultrasound Criteria for Arterial Invasion in Pancreatic Cancer of the Body and Tail. Co-author DOI 10.1097/mpa.0000000000001523↗
  37. Needle tract seeding recurrence of pancreatic cancer in the gastric wall with paragastric lymph node metastasis after endoscopic ultrasound-guided fine needle … Last author DOI 10.1186/s12876-020-1159-x↗
  38. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues. Last author DOI 10.1007/s00595-019-01804-x↗
  39. Is hepatic artery coil embolization useful in distal pancreatectomy with en bloc celiac axis resection for locally advanced pancreatic cancer? Last author DOI 10.1186/s12957-019-1667-8↗
  40. Successful treatment of a locally advanced unresectable pancreatic cancer patient with interstitial pneumonitis by conversion surgery following gemcitabine plu… Last author DOI 10.3892/mco.2019.1807↗
  41. Expression of annexin II and stromal tenascin C promotes epithelial to mesenchymal transition and correlates with distant metastasis in pancreatic cancer. Last author DOI 10.3892/ijmm.2018.3652↗
  42. Conversion surgery with gemcitabine plus nab-paclitaxel for locally advanced unresectable pancreatic cancer: A case report. Last author DOI 10.3892/mco.2018.1688↗
  43. [Pancreas Bed Recurrence Resection Combined with Celiac and Common Hepatic Arterial Resection after Distal Pancreatectomy for Pancreatic Cancer]. Co-author PMID 29362327↗
  44. Grainyhead-like 2 (GRHL2) regulates epithelial plasticity in pancreatic cancer progression. Last author DOI 10.1002/cam4.1212↗
  45. Duffy antigen receptor for chemokines (DARC) expressing in cancer cells inhibits tumor progression by suppressing CXCR2 signaling in human pancreatic ductal ad… Last author DOI 10.1016/j.cyto.2017.02.007↗
  46. Sex Determining Region Y Box 9 Induces Chemoresistance in Pancreatic Cancer Cells by Induction of Putative Cancer Stem Cell Characteristics and Its High Expres… Co-author DOI 10.1097/mpa.0000000000000945↗
  47. Metadherin promotes metastasis by supporting putative cancer stem cell properties and epithelial plasticity in pancreatic cancer. Last author DOI 10.18632/oncotarget.19802↗
  48. [IV. Distal Pancreatectomy with Celiac Axis Resection(DP-CAR)for Locally Advanced Pancreatic Cancer with Celiac Artery Invasion]. Last author PMID 29066679↗
  49. Identification of a novel serum biomarker for pancreatic cancer, C4b-binding protein α-chain (C4BPA) by quantitative proteomic analysis using tandem mass tags. Co-author DOI 10.1038/bjc.2016.295↗
  50. Low Stromal Area and High Stromal Microvessel Density Predict Poor Prognosis in Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000499↗

Closest collaborators

The 25 strongest of 169 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shigetsugu Takano · 41 shared papers, 2012–2026 · strength 5.28
  2. Katsunori Furukawa · 25 shared papers, 2012–2022 · strength 2.11
  3. Hideyuki Yoshitomi · 26 shared papers, 2012–2021 · strength 1.92
  4. Takanori Konishi · 8 shared papers, 2021–2026 · strength 1.66
  5. Masaru Miyazaki · 21 shared papers, 2012–2022 · strength 1.46
  6. Shingo Kagawa · 18 shared papers, 2012–2021 · strength 1.21
  7. Kazuyuki Sogawa · 6 shared papers, 2016–2026 · strength 1.02
  8. Ryotaro Eto · 4 shared papers, 2023–2026 · strength 0.96
  9. Satoshi Hirano · 5 shared papers, 2025–2026 · strength 0.95
  10. Kensuke Suzuki · 6 shared papers, 2017–2025 · strength 0.90
  11. Hiroki Yamaue · 5 shared papers, 2023–2026 · strength 0.89
  12. Itaru Endo · 5 shared papers, 2023–2026 · strength 0.89
  13. Yohei Miyagi · 4 shared papers, 2023–2026 · strength 0.86
  14. Shunsuke Tabe · 4 shared papers, 2023–2026 · strength 0.86
  15. Hideki Taniguchi · 4 shared papers, 2023–2026 · strength 0.86
  16. Kenta Takeuchi · 4 shared papers, 2023–2026 · strength 0.86
  17. Hitoe Nishino · 6 shared papers, 2017–2024 · strength 0.85
  18. Sohei Satoi · 4 shared papers, 2025–2026 · strength 0.76
  19. Soichiro Morinaga · 4 shared papers, 2023–2025 · strength 0.75
  20. Michiaki Unno · 4 shared papers, 2023–2026 · strength 0.73
  21. Yuya Yamamoto · 3 shared papers, 2025–2026 · strength 0.70
  22. Yoji Miyahara · 6 shared papers, 2015–2022 · strength 0.67
  23. Goro Honda · 3 shared papers, 2025–2026 · strength 0.60
  24. Takashi Kishimoto · 4 shared papers, 2020–2024 · strength 0.60
  25. Satoshi Tomizawa · 3 shared papers, 2021–2023 · strength 0.52

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.